These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 26100706

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS, Suh JY, Peck KR, Lee MY, Oh WS, Kwon KT, Jung DS, Lee NY, Song JH.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.
    Ellington MJ, Livermore DM, Pitt TL, Hall LM, Woodford N.
    J Antimicrob Chemother; 2006 Oct; 58(4):848-52. PubMed ID: 16891630
    [Abstract] [Full Text] [Related]

  • 26. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S, Gençer S, Batırel A, Hacıseyitoğlu D, Ozer S.
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [Abstract] [Full Text] [Related]

  • 27. Investigations on In Vivo Pharmacokinetic/Pharmacodynamic Determinants of Fosfomycin in Murine Thigh and Kidney Infection Models.
    Chavan R, Naphade B, Waykar B, Bhagwat S.
    Microb Drug Resist; 2023 Jan; 29(1):18-27. PubMed ID: 36346323
    [Abstract] [Full Text] [Related]

  • 28. In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin against Escherichia coli in a Neutropenic Murine Thigh Infection Model.
    Zhou YF, Tao MT, He YZ, Sun J, Liu YH, Liao XP.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038275
    [Abstract] [Full Text] [Related]

  • 29. Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model.
    Abbott IJ, van Gorp E, van der Meijden A, Wijma RA, Meletiadis J, Roberts JA, Mouton JW, Peleg AY.
    Antimicrob Agents Chemother; 2020 May 21; 64(6):. PubMed ID: 32253214
    [Abstract] [Full Text] [Related]

  • 30. ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.
    Burgos RM, Rodvold KA.
    Future Microbiol; 2019 Apr 21; 14():461-475. PubMed ID: 30854892
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems.
    VanScoy BD, Lakota EA, Conde H, Fikes S, Bhavnani SM, Elefante PB, Scangarella-Oman NE, Ambrose PG.
    Antimicrob Agents Chemother; 2021 Nov 17; 65(12):e0012221. PubMed ID: 34543096
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study.
    Sahni RD, Balaji V, Varghese R, John J, Tansarli GS, Falagas ME.
    Future Microbiol; 2013 May 17; 8(5):675-80. PubMed ID: 23642120
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. In vitro susceptibility of canine and feline Escherichia coli to fosfomycin.
    Hubka P, Boothe DM.
    Vet Microbiol; 2011 Apr 21; 149(1-2):277-82. PubMed ID: 21168287
    [Abstract] [Full Text] [Related]

  • 37. Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome.
    Abbott IJ, van Gorp E, Wijma RA, Meletiadis J, Roberts JA, Mouton JW, Peleg AY.
    Antimicrob Agents Chemother; 2020 Feb 21; 64(3):. PubMed ID: 31907184
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections.
    Abbott IJ, Dekker J, van Gorp E, Wijma RA, Raaphorst MN, Klaassen CHW, Meletiadis J, Mouton JW, Peleg AY.
    J Antimicrob Chemother; 2020 Apr 01; 75(4):988-996. PubMed ID: 31873748
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.